Detecting HPV DNA in Anal and Cervical Cancers

NCT ID: NCT04857528

Last Updated: 2025-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-06

Study Completion Date

2027-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more information about HPV-associated cancers and how they respond to treatment. Participation in this study will last approximately 2 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer Anal Cancer HPV-Related Anal Squamous Cell Carcinoma HPV-Related Cervical Carcinoma HPV-Related Carcinoma Uterine Cervical Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Retrospective (Participants Who Have Already Been Treated for HPV-Related Cancer Before Study)

This group will use medical records from participants who have already received chemoradiation for their HPV-related anal or cervical cancer at a time before this study started. Because they have already received treatment, these participants will provide previous blood/tumor tissue samples that contain detectable HPV DNA as well as at least one post-treatment sample that their doctor collected before the study. Data from these previously collected samples will be compared to current samples from participants who are actively enrolled in this study in present day (chart review).

No interventions assigned to this group

Prospective (Participants Who Will Receive Radiation Treatment for HPV-Related Cancer During Study)

This group is for participants who plan to receive radiation treatment (with or without chemotherapy) for their HPV-related anal or cervical cancer during the time this study will be conducted. Participants in this group will sign a consent form allowing researchers to collect their blood samples and analyze/compare them to the samples from the retrospective group of participants.

Radiation Treatment With or Without Chemotherapy

Intervention Type RADIATION

Standard care radiation treatment.

Blood Sample Collection

Intervention Type OTHER

Researchers will collect blood samples from participants before, during and after radiation treatment. Approximately 6 teaspoons of blood will be collected each time blood is drawn.

HPV Genotyping (HPV DNA Test)

Intervention Type DIAGNOSTIC_TEST

A test used to detect the type of HPV DNA found in the participant's blood and tumor tissue samples.

Testing Archival Tumor Tissue

Intervention Type DIAGNOSTIC_TEST

Tumor tissue will be tested in a lab for all cervical cancer participants and some participants with anal cancer as assessed by the lead study doctor. This tumor tissue sample will be from a previous biopsy that the participant received before the study per standard care; no new biopsy will be required for this study.

Physical Exam

Intervention Type OTHER

A physical exam will be given 12 months after radiation treatment. This physical exam may also include an anoscopy (a procedure to examine the anus using a device inserted into the anus) or sigmoidoscopy (a procedure that looks at the rectum and lower part of the colon using a device inserted into the anus).

Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)

Intervention Type DIAGNOSTIC_TEST

Tests that use computers and/or rotating x-rays to scan/create images of the body.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiation Treatment With or Without Chemotherapy

Standard care radiation treatment.

Intervention Type RADIATION

Blood Sample Collection

Researchers will collect blood samples from participants before, during and after radiation treatment. Approximately 6 teaspoons of blood will be collected each time blood is drawn.

Intervention Type OTHER

HPV Genotyping (HPV DNA Test)

A test used to detect the type of HPV DNA found in the participant's blood and tumor tissue samples.

Intervention Type DIAGNOSTIC_TEST

Testing Archival Tumor Tissue

Tumor tissue will be tested in a lab for all cervical cancer participants and some participants with anal cancer as assessed by the lead study doctor. This tumor tissue sample will be from a previous biopsy that the participant received before the study per standard care; no new biopsy will be required for this study.

Intervention Type DIAGNOSTIC_TEST

Physical Exam

A physical exam will be given 12 months after radiation treatment. This physical exam may also include an anoscopy (a procedure to examine the anus using a device inserted into the anus) or sigmoidoscopy (a procedure that looks at the rectum and lower part of the colon using a device inserted into the anus).

Intervention Type OTHER

Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)

Tests that use computers and/or rotating x-rays to scan/create images of the body.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stage I-III anal cancer or stage I-IVA cervical cancer that is p16+ based on immunohistochemistry.
* Age ≥ 18 years
* Planned to undergo radiation therapy as definitive treatment, with or without concurrent systemic therapy

Exclusion Criteria

* Anal carcinoma not associated with HPV-16, 18, 31, 33, or 35 will be removed from the
* Planned to undergo radiation therapy as an adjuvant or post-operative therapy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Chicago

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christina Son, MD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB20-0410

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.